COMMUNIQUÉS West-GlobeNewswire

Kamada Issues 2024 CEO Letter to Shareholders
06/03/2024
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for [...]
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
06/03/2024
Data published in Molecular Cancer Therapeutics describes the scientific background underlying the design, discovery and optimization of palazestrant (OP-1250) Pre-clinical results demonstrate that palazestrant, as both [...]
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
06/03/2024
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today [...]
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
06/03/2024
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
06/03/2024
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA [...]
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
06/03/2024
HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and [...]
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
06/03/2024
NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision expected in 4Q 2024 Announced [...]
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
06/03/2024
LYON, France, March 6, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a [...]
Crescendo Biologics to present at the 2024 AACR Annual Meeting
06/03/2024
Crescendo Biologics to present at the 2024 AACR Annual Meeting Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing [...]
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
06/03/2024
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.m. ET to report [...]
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
06/03/2024
- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) [...]
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
06/03/2024
Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show [...]
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
06/03/2024
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today [...]
Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
06/03/2024
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd ("Psyence [...]
Breckenridge Brewery Channels the Luck of The Irish With Nitro Irish Stout and Go Gold Sweepstakes
06/03/2024
Win a Trip for Two to Ireland LITTLETON, Colo., March 06, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery (“Breck Brew”) , a subsidiary of Tilray Brands, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY and TSX: TLRY), [...]
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
06/03/2024
Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional Superkine, MDNA113, will also be presented at the Annual Meeting TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna [...]
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
06/03/2024
- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Completed enrollment of third dose cohort in Phase 1 trial [...]
Interactive Strength Inc. (Nasdaq: TRNR) to Exhibit Both CLMBR and FORME Lift at IHRSA in Los Angeles March 6-8
06/03/2024
CLMBR is Receiving Significant Interest From Gyms for use on the Cardio Floor and in the Group Fitness Room as a Replacement for Spin Bike FORME is Receiving the Highest Interest From Country Clubs and Multi-family [...]
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
06/03/2024
Total Revenues for Fiscal Year 2023 of $142.5 Million, Representing All-Time Record Annual Revenues and Up 10% Compared to Fiscal Year 2022 Fiscal Year 2023 Adjusted EBITDA of $24.1 Million, Up 35% Year-over-Year Strong [...]

Pages